

# STATE OF NEW YORK

2142--A

2025-2026 Regular Sessions

## IN ASSEMBLY

January 15, 2025

Introduced by M. of A. PAULIN, LUPARDO, HEVESI, McDONALD, WEPRIN, BURDICK -- read once and referred to the Committee on Health -- recommitted to the Committee on Health in accordance with Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the public health law and the penal law, in relation to authorizing the use of psilocybin to treat qualified medical conditions

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1 Section 1. This act shall be known and may be cited as the "medical  
2 psilocybin act".

3 § 2. Article 33 of the public health law is amended by adding a new  
4 title 5-B to read as follows:

### TITLE V-B

#### MEDICAL PSILOCYBIN ACT

##### Section 3369-aa. Definitions.

3369-bb. Medical use of psilocybin program.

3369-cc. Registry identification cards.

3369-dd. Exemption from criminal and civil penalties for  
possession and medical use of psilocybin.

3369-ee. Prohibitions, restrictions and limitations on the use  
of psilocybin.

3369-ff. Recordkeeping.

3369-gg. Labelling; warnings.

3369-hh. Safety and testing requirements.

3369-ii. Violations.

3369-jj. Reporting.

3369-kk. Protections for the medical use of psilocybin.

##### § 3369-aa. Definitions. As used in this title:

1. "Designated caregiver" means the individual designated by a qualified patient in a registry application. A qualified patient may designate up to two caregivers;

EXPLANATION--Matter in italics (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD03342-02-6

1 2. "Licensed healthcare provider" means a person who: (a) is licensed  
2 as a physician, a psychologist or a nurse practitioner under title eight  
3 of the education law; and (b) has completed a two to four hour course as  
4 determined by the commissioner in regulations; provided however, a  
5 registration shall not be denied without cause. Such course may count  
6 toward board certification requirements. To be a licensed healthcare  
7 provider under this title, such licensed professional's authorized scope  
8 of practice does not need to, but may include, medical diagnosis or  
9 treatment of a qualifying health condition or the prescription of medi-  
10 cations;

11 3. "Licensed producer" means a person or business enterprise, includ-  
12 ing a sole proprietorship, partnership, corporation, limited liability  
13 company, or other business enterprise, who or which has a license from  
14 the department pursuant to this title to grow and harvest or prepare  
15 psilocybin from psilocybin-producing mushrooms, including to compound,  
16 convert, process or manufacture psilocybin products directly or indi-  
17 rectly from psilocybin mushrooms, to package or repackage or label or  
18 relabel the products, and to transport and deliver psilocybin and psilo-  
19 cybin products;

20 4. "Permitted medical use" means the quantity of psilocybin, dosing  
21 parameters, method of administration, setting, and whether supervised  
22 use is required, for an individual qualified patient as determined by a  
23 licensed healthcare provider as part of an individualized treatment  
24 plan;

25 5. "Psilocybin" means the naturally occurring psychedelic compound  
26 4-phosphoryloxy-N,N-dimethyltryptamine, also known as 4-PO-DMT, and its  
27 pharmacologically active metabolite psilocin,  
28 4-hydroxy-N,N-dimethyltryptamine, found in certain mushrooms, but does  
29 not include synthetic or synthetic analogs of psilocybin;

30 6. "Qualified patient" means a patient whose licensed healthcare  
31 provider has judged to be a medically appropriate candidate for the use  
32 of medical psilocybin based on being diagnosed with a qualifying condi-  
33 tion;

34 7. "Qualifying condition" includes:

35 (a) major treatment-resistant depression;

36 (b) post-traumatic stress disorder;

37 (c) substance use disorders;

38 (d) end-of-life care;

39 (e) cluster headaches; and

40 (f) other conditions approved by the department;

41 8. "Qualified supervisor" means an individual who meets training and  
42 qualification standards established by the department and is authorized  
43 by the department to supervise the use of psilocybin by qualified  
44 patients. A qualified supervisor need not be a licensed healthcare  
45 provider; and

46 9. "Supervised use" means the administration of psilocybin in the  
47 presence of a licensed healthcare provider, a licensed healthcare  
48 provider's authorized staff, or a qualified supervisor.

49 § 3369-bb. Medical use of psilocybin program. 1. The "medical use of  
50 psilocybin program" or "the program" is hereby created within the  
51 department. In developing the program, the department shall establish:

52 (a) procedures for the issuance, renewal, suspension, and revocation  
53 of licenses, registrations, or permits necessary for the implementation  
54 and operation of the program;

55 (b) appropriate requirements for licensed producers, licensed health-  
56 care providers and qualified patients;

1 (c) criteria and a process for licensure and registration of psilocy-  
2 bin producers;

3 (d) necessary initial and ongoing training for licensed producers,  
4 licensed healthcare providers and qualified supervisors;

5 (e) appropriate qualifications, education and training standards for  
6 qualified supervisors;

7 (f) treatment protocols, including patient selection criteria, medical  
8 service standards, dosage standards and approved settings for adminis-  
9 tration of psilocybin to qualified patients;

10 (g) requirements and standards for supervised use that are focused on  
11 safety and efficacy;

12 (h) safety protocols for producing psilocybin from mushrooms, trans-  
13 porting, storing, handling and dispensing psilocybin to qualified  
14 patients, licensed healthcare providers, qualified supervisors, or other  
15 individuals authorized by the department;

16 (i) registry identification systems for patients and designated care-  
17 givers;

18 (j) other best practices for licensed producers, licensed healthcare  
19 providers and qualified supervisors;

20 (k) requirements for data collection to evaluate the program and the  
21 use of best practices by licensed producers, licensed healthcare provid-  
22 ers, and qualified supervisors; and

23 (l) other requirements, restrictions and limitations deemed necessary  
24 by the department.

25 2. The department shall require that either the qualified patient or  
26 the licensed healthcare provider who is recommending psilocybin and  
27 treating such patient be a New York state resident.

28 3. The department shall monitor licensed producers, licensed health-  
29 care providers, and qualified supervisors to ensure compliance with the  
30 provisions of this title and the rules and regulations promulgated  
31 therefor.

32 4. The department shall consult with the department of mental hygiene  
33 in developing best practices, including best settings for administration  
34 of psilocybin. Subject to the regulations of the department, a licensed  
35 healthcare provider or qualified supervisor shall determine the appro-  
36 priate setting on a case-by-case basis for qualified patients.

37 5. The department shall develop and require labels warning consumers  
38 of any potential impact on human health resulting from the consumption  
39 of psilocybin products that shall be affixed to those products when  
40 sold, if such labels are deemed warranted by the department and may  
41 establish standardized and/or uniform packaging and labeling require-  
42 ments for medical use psilocybin products.

43 6. Psilocybin shall be dispensed in a sealed and properly labeled  
44 package. The labeling shall contain: (a) the information required to be  
45 included in the receipt provided to the qualified patient by the  
46 licensed producer; (b) the packaging date; (c) any applicable date by  
47 which the psilocybin should be used; (d) the amount of individual doses  
48 contained within; (e) usage instructions; and (f) a warning that the  
49 psilocybin must be kept in the original container in which it was  
50 dispensed except for the portion removed for immediate consumption.

51 7. Other than as set forth in subdivision eight of this section, a  
52 licensed producer may, in accordance with a qualified patient's permit-  
53 ted medical use, transport and deliver psilocybin to: (a) a qualified  
54 patient; (b) a licensed healthcare provider; (c) a qualified supervisor;  
55 or (d) an authorized designated caregiver.

1 8. Psilocybin intended for supervised use as required by the qualified  
2 patient's permitted medical use shall only be delivered directly to a  
3 licensed healthcare provider, a licensed healthcare provider's author-  
4 ized staff, or to a qualified supervisor.

5 9. (a) No licensed producer may sell, deliver, distribute or dispense  
6 a quantity of psilocybin larger than, or in a manner inconsistent with,  
7 a qualified patient's permitted medical use as allowed under this title.

8 (b) When dispensing psilocybin to a qualified patient, the licensed  
9 producer shall not dispense an amount greater than a thirty day supply  
10 of the dosage as determined by the licensed healthcare provider,  
11 consistent with the qualified patient's permitted medical use, or, if  
12 not specified by the licensed healthcare provider, by the department  
13 through regulation, which may include qualifying condition-specific  
14 standards for dosing, administration, setting, and supervised use.

15 § 3369-cc. Registry identification cards. 1. Upon a determination of  
16 qualification of a patient by a licensed healthcare provider to partic-  
17 ipate in the program under this title, the department shall issue a  
18 registry identification card for such qualified patient. A registry  
19 identification card shall expire as provided in this section. The  
20 department may specify a form for a registry application, in which case  
21 the department shall provide the form on request, reproductions of the  
22 form may be used, and the form shall be available for downloading from  
23 the department's website.

24 2. To obtain, amend or renew a registry identification card, a quali-  
25 fied patient shall file a registry application with the department. The  
26 registry application or renewal application shall include:

27 (a) (i) the licensed healthcare provider's determination of the  
28 patient's qualification under this title;

29 (ii) the name, address, and date of birth of the patient;

30 (iii) the date of the qualification;

31 (iv) if the patient has a registry identification card based on a  
32 current valid certification, the registry identification number and  
33 expiration date of that registry identification card;

34 (v) the specified date until which the patient would benefit from  
35 psilocybin use, if the certification states such a date;

36 (vi) the name, address, federal registration number, if any, and tele-  
37 phone number of the licensed healthcare provider;

38 (vii) any recommendation or limitation by the provider as to the form  
39 or forms of psilocybin or dosage for the qualified patient and whether  
40 or not supervised use is required; and

41 (viii) other individual identifying information required by the  
42 department;

43 (b) in the case of a qualified patient, if the patient designates a  
44 designated caregiver, the name, address, and date of birth of the desig-  
45 nated caregiver, and other individual identifying information required  
46 by the department;

47 (c) in the case of a designated caregiver:

48 (i) the name, address, and date of birth of the designated caregiver;  
49 and

50 (ii) if the designated caregiver has a registry identification card,  
51 the registry identification number and expiration date of that registry  
52 identification card;

53 (d) a statement that a false statement made in the application is  
54 punishable under section 210.45 of the penal law;

55 (e) the date of the application and the signature of the qualified  
56 patient; and

1 (f) any other requirements determined by the commissioner.

2 3. A registry identification card shall:

3 (a) contain the name of the qualified patient or the designated care-  
4 giver;

5 (b) contain the date of issuance and expiration date of the registry  
6 identification card;

7 (c) contain a registry identification number for the qualified patient  
8 or the designated caregiver, and a registry identification number;

9 (d) contain a photograph of the individual to whom the registry iden-  
10 tification card is being issued, which shall be obtained by the depart-  
11 ment in a manner specified by the commissioner in regulations; provided,  
12 however, that if the department requires qualified patients to submit  
13 photographs for this purpose, there shall be a reasonable accommodation  
14 of qualified patients who are confined to their homes due to their  
15 medical conditions and may therefore have difficulty procuring photo-  
16 graphs;

17 (e) be a secure document as determined by the department;

18 (f) plainly state any recommendation or limitation by the licensed  
19 healthcare provider as to the form or forms of psilocybin or dosage for  
20 the qualified patient; and

21 (g) any other requirements determined by the commissioner.

22 4. The department shall maintain a confidential list of the persons to  
23 whom it has issued registry identification cards. Individual identifying  
24 information obtained by the department under this title shall be confi-  
25 dential and exempt from disclosure under article six of the public offi-  
26 cers law. Notwithstanding this subdivision, the department may notify  
27 any appropriate law enforcement agency of information relating to any  
28 violation or suspected violation of this title.

29 5. The department shall verify to law enforcement personnel in an  
30 appropriate case whether a registry identification card is valid.

31 6. If a qualified patient willfully violates any provision of this  
32 title as determined by the department, their registry identification  
33 card may be suspended or revoked, in addition to any other penalty that  
34 may apply.

35 7. The department shall establish a registry system for designated  
36 caregivers who may assist qualified patients, including in obtaining and  
37 transporting psilocybin, subject to department regulations.

38 8. The department may waive the requirement for a registry identifica-  
39 tion card for certain categories of qualified patients, including but  
40 not limited to:

41 (a) qualified patients receiving a limited number of supervised admin-  
42 istrations;

43 (b) qualified patients receiving care in end-of-life settings; or

44 (c) other categories of qualified patients where the department deter-  
45 mines that registry identification cards are not necessary or appropri-  
46 ate.

47 § 3369-dd. Exemption from criminal and civil penalties for possession  
48 and medical use of psilocybin. 1. (a) A licensed producer shall not be  
49 subject to arrest, prosecution or penalty for the manufacture,  
50 possession, transportation, delivery or sale of psilocybin which is in  
51 accordance with the provisions of this title.

52 (b) A licensed producer, licensed healthcare provider, qualified  
53 supervisor, or a qualified patient shall not be subject to arrest, pros-  
54 ecution or penalty for possessing or transporting psilocybin consistent  
55 with a qualified patient's permitted medical use and in a quantity not

1 more than allowed by department regulations and in accordance with the  
2 provisions of this title.

3 (c) A licensed healthcare provider or qualified supervisor shall not  
4 be subject to arrest, prosecution or penalty for providing, and/or  
5 administering psilocybin in accordance with the regulations promulgated  
6 under this title.

7 (d) A qualified patient shall not be subject to arrest, prosecution or  
8 penalty for the possession and use of psilocybin for medical purposes in  
9 dosages which are in accordance with the regulations promulgated under  
10 this title.

11 (e) A qualified patient, designated caregiver, licensed healthcare  
12 provider, qualified supervisor, licensed producer, or other individual  
13 authorized by the department, shall not be subject to arrest, prose-  
14 cution, or penalty in any manner, or denied any right or privilege,  
15 including but not limited to civil penalty or disciplinary action by a  
16 business or occupational or professional licensing board or bureau,  
17 solely for actions and conduct in accordance with this title.

18 2. The provisions of this title shall not apply to federal food and  
19 drug administration-approved clinical trials, or to federal food and  
20 drug administration-approved products which contain psilocybin.

21 3. A person currently under state or local supervision, including but  
22 not limited to probation, parole, release on bail awaiting trial, or who  
23 is in the custody or under the supervision of the department of  
24 corrections and community supervision shall not be penalized for partic-  
25 ipation in the program.

26 § 3369-ee. Prohibitions, restrictions and limitations on the  
27 possession and use of psilocybin. 1. Participation in the medical use of  
28 psilocybin program by a licensed producer, licensed healthcare provider,  
29 qualified supervisor, or qualified patient does not relieve the produc-  
30 er, licensed healthcare provider, qualified supervisor or qualified  
31 patient from:

32 (a) criminal prosecution or civil penalties for activities not author-  
33 ized under this title; or

34 (b) liability for damages or criminal prosecution arising out of the  
35 operation of a motor vehicle while under the influence of psilocybin.

36 2. Psilocybin shall only be dispensed by a licensed producer to a  
37 qualified patient, a licensed healthcare provider and their authorized  
38 staff, a qualified supervisor, or an individual otherwise authorized by  
39 the department as allowed by department regulation and consistent with  
40 the provisions of this title.

41 3. The amount of psilocybin that may be possessed by, or on behalf of,  
42 a qualified patient shall not exceed a thirty day supply, as determined  
43 by the qualifying patient's permitted medical use and department rule.

44 4. A person who makes a fraudulent representation to a law enforcement  
45 officer about the person's participation in the program to avoid arrest  
46 or prosecution for a psilocybin-related offense is guilty of a misdemea-  
47 nor.

48 5. For the purposes of this title, psilocybin shall not be deemed to  
49 be a "drug" for purposes of article one hundred thirty-seven of the  
50 education law and is not intended to be distributed through any pharma-  
51 cy.

52 6. Nothing in this title permits or authorizes the promotion of use of  
53 psilocybin as a drug, substance, or product intended to diagnose, treat,  
54 cure, or prevent any disease or mental health or other health condi-  
55 tions.

1 § 3369-ff. Recordkeeping. 1. A licensed producer shall maintain  
2 records of all production and sales of psilocybin containing products.  
3 Upon request by the department, a licensed producer shall produce such  
4 records and permit annual inspections of any facilities utilized by such  
5 producer for such purpose.

6 2. The department shall maintain a registry of licensed producers.

7 § 3369-gg. Labelling; warnings. A licensed producer shall clearly  
8 label any psilocybin or psilocybin-containing product with the full name  
9 of the licensed producer, the producer's office address, a description  
10 of contents of the product including the strain and the culture-specific  
11 approximate psilocybin equivalent potency; and any warning label  
12 required by the department pursuant to section thirty-three hundred  
13 sixty-nine-bb of this title.

14 § 3369-hh. Safety and testing requirements. 1. As is necessary to  
15 protect the public health and safety the department shall adopt rules  
16 and regulations:

17 (a) Establishing standards for testing psilocybin products.

18 (b) Identifying appropriate tests for psilocybin products, depending  
19 on the type of psilocybin product and the manner in which the psilocybin  
20 product was manufactured, that are necessary to protect the public  
21 health and safety, which may include, but not be limited to, tests for:

22 (i) Microbiological contaminants;

23 (ii) Pesticides;

24 (iii) Other contaminants;

25 (iv) Solvents or residual solvents; and

26 (v) Psilocybin concentration.

27 (c) Establishing procedures for determining batch sizes and for sampl-  
28 ing psilocybin products.

29 (d) Establishing different minimum standards for different varieties  
30 of psilocybin products.

31 2. In addition to the testing requirements established under subdivi-  
32 sion one of this section, the department may require psilocybin products  
33 to be tested in accordance with any applicable law of this state, or any  
34 applicable rule adopted under a law of this state, related to the  
35 production and processing of food products or commodities.

36 3. In adopting rules and regulations under this subdivision the  
37 department may require a licensed producer to test psilocybin products  
38 before selling or transferring the psilocybin products.

39 4. The department may conduct random testing of psilocybin products  
40 for the purpose of determining whether a licensee subject to testing is  
41 in compliance with this subdivision.

42 § 3369-ii. Violations. 1. Psilocybin licensed producers who are in  
43 violation of this title may be penalized by loss of such license permit  
44 for a period of two years and, after such penalization period, shall  
45 subsequently be entitled to apply for a psilocybin permit.

46 2. The department may revoke the authority of a licensed producer to  
47 participate in the program.

48 § 3369-jj. Reporting. The department shall promulgate regulations for  
49 the collection of data from licensed producers, licensed healthcare  
50 providers, qualified supervisors and qualified patients as a means to  
51 evaluate the effectiveness of the medical use of psilocybin. The depart-  
52 ment shall annually report its findings to the legislature. Data shall  
53 be reported in such a way that any individual qualified patients cannot  
54 be identified.

55 § 3369-kk. Protections for the medical use of psilocybin. 1. Being a  
56 qualified patient shall be deemed to be having a "disability" under

1 article fifteen of the executive law, section forty-c of the civil  
2 rights law, sections 240.00, 485.00, and 485.05 of the penal law, and  
3 section 200.50 of the criminal procedure law. This subdivision shall not  
4 bar the enforcement of a policy prohibiting an employee from performing  
5 their employment duties while impaired by a controlled substance. This  
6 subdivision shall not require any person or entity to do any act that  
7 would put the person or entity in direct violation of federal law or  
8 cause it to lose a federal contract or funding.

9 2. The fact that a person is a qualified patient and/or acting in  
10 accordance with this title, shall not be a consideration in a proceeding  
11 pursuant to applicable sections of the domestic relations law, the  
12 social services law and the family court act.

13 3. (a) Any qualified patient information contained shall be deemed  
14 exempt from public disclosure under sections eighty-seven and eighty-  
15 nine of the public officers law. Upon specific request by a qualified  
16 patient to the department, the department shall verify the requesting  
17 patient's status as a valid qualified patient to the patient's school or  
18 employer or other designated party, to ensure compliance with the  
19 protections afforded by this section.

20 (b) The name, contact information, and other information relating to a  
21 licensed healthcare provider's qualifying patients under this title  
22 shall be public information and shall be maintained on the department's  
23 website accessible to the public in searchable form. However, if a  
24 licensed healthcare provider notifies the board in writing that they do  
25 not want their name and other information disclosed, that licensed  
26 healthcare provider's name and other information shall thereafter not be  
27 public information or maintained on the department's website, unless the  
28 licensed healthcare provider cancels the request.

29 4. A person currently under parole, probation or other state or local  
30 supervision, or released on bail awaiting trial may not be punished or  
31 otherwise penalized for conduct allowed under this title.

32 5. Employees who use medical psilocybin shall be afforded the same  
33 rights, procedures and protections that are available and applicable to  
34 injured workers under the workers' compensation law, or any rules or  
35 regulations promulgated thereunder, when such injured workers are  
36 prescribed medications that may prohibit, restrict, or require the  
37 modification of the performance of their duties.

38 § 3. The penal law is amended by adding a new article 174 to read as  
39 follows:

#### 40 ARTICLE 174

##### 41 CRIMINAL DIVERSION OF MEDICAL PSILOCYBIN

42 Section 174.00 Criminal diversion of medical psilocybin; definitions.

43 174.05 Criminal diversion of medical psilocybin; limitations.

44 174.10 Criminal diversion of medical psilocybin in the first  
45 degree.

46 174.11 Criminal diversion of medical psilocybin in the second  
47 degree.

48 174.15 Criminal retention of medical psilocybin.

49 174.20 Relationship to other controlled substances offenses.

50 § 174.00 Criminal diversion of medical psilocybin; definitions.

51 The following definitions are applicable to this article:

52 1. "Medical psilocybin" means psilocybin as defined in subdivision  
53 five of section thirty-three hundred sixty-nine-aa of the public health  
54 law which is provided to a qualifying patient pursuant to title five-B  
55 of article thirty-three of the public health law.

1 2. "Licensure" means a license made under section thirty-three hundred  
2 sixty-nine-bb of the public health law.

3 § 174.05 Criminal diversion of medical psilocybin; limitations.

4 The provisions of this article shall not apply to:

5 1. a licensed healthcare provider authorized to recommend and/or  
6 administer medical psilocybin under title five-B of article thirty-three  
7 of the public health law who acted in good faith in the lawful course of  
8 their profession; or

9 2. a licensed producer as that term is defined in subdivision three of  
10 section thirty-three hundred sixty-nine-aa of the public health law who  
11 acted in good faith; or

12 3. a person who acted in good faith seeking treatment for a medical  
13 condition or assisting another person to obtain treatment for a medical  
14 condition.

15 § 174.10 Criminal diversion of medical psilocybin in the first degree.

16 A person is guilty of criminal diversion of medical psilocybin in the  
17 first degree when such person is a licensed healthcare provider or qual-  
18 ified supervisor, as defined in subdivision two of section thirty-three  
19 hundred sixty-nine-aa of the public health law, who recommends or admin-  
20 isters with knowledge of reasonable grounds to know that (i) the recipi-  
21 ent has no medical need for it, or (ii) it is for a purpose other than  
22 to treat a qualifying condition as defined in subdivision seven of  
23 section thirty-three hundred sixty-nine-aa of the public health law.

24 Criminal diversion of medical psilocybin in the first degree is a  
25 class E felony.

26 § 174.11 Criminal diversion of medical psilocybin in the second degree.

27 A person is guilty of criminal diversion of medical psilocybin in the  
28 second degree when such person sells, trades, delivers, or otherwise  
29 provides medical psilocybin to another with knowledge or reasonable  
30 grounds to know that the recipient is not registered under title five-B  
31 of article thirty-three of the public health law.

32 Criminal diversion of medical psilocybin in the second degree is a  
33 class B misdemeanor.

34 § 174.15 Criminal retention of medical psilocybin.

35 A person is guilty of criminal retention of medical psilocybin when,  
36 being a qualifying patient as such term is defined in subdivision six of  
37 section thirty-three hundred sixty-nine-aa of the public health law,  
38 respectively, such person knowingly obtains, possesses, stores or main-  
39 tains an amount of psilocybin in excess of the amount they are author-  
40 ized to possess under the provisions of title five-B of article thirty-  
41 three of the public health law.

42 Criminal retention of medical psilocybin is a class A misdemeanor.

43 § 174.20 Relationship to other controlled substances offenses.

44 A person shall not be convicted of both an offense defined in this  
45 article and an offense defined in article two hundred twenty of this  
46 chapter based on the same act or transaction. The provisions of this  
47 article shall be construed to avoid duplicative punishment. A person may  
48 be prosecuted under this article or under article two hundred twenty of  
49 this chapter, but not both for the same act or transaction.

50 § 4. This act shall take effect July 1, 2028. Effective immediately,  
51 the addition, amendment and/or repeal of any rule or regulation neces-  
52 sary for the implementation of this act on its effective date are  
53 authorized to be made and completed on or before such date.